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Abstract
Background: In hemodialysis patients, post-dialysis treatment with intravenous antibiotics permits even severe
infections to be managed on an outpatient basis. Cefepime is a fourth-generation cephalosporin with a broad
spectrum of action in monotherapy. We report on the pharmacokinetics of cefepime in post-dialysis therapy.
Methods: Since June 2012, twelve infections were treated with post-dialysis cefepime in 9 patients on high-flux
hemodialysis. The initial post-dialysis dose of cefepime was approximately 15 mg/kg. The following doses were
adapted according to the trough serum levels obtained before the subsequent dialysis in order to be above the
EUCAST breakpoints for susceptible organisms and above the MIC90. Residual plasma concentrations were determined
before (n = 30) and after (n = 17) dialysis by liquid chromatography–mass spectrometry.
Results: Overall, the mean ± SD dose of cefepime was 920 ± 270 mg (14.5 ± 5.1 mg/kg), but it was significantly lower
before the 48 h interval (775 ± 210 mg or 12.7 ± 4.5 mg/kg) compared to the 72 h interval (1125 ± 225 mg or 17.2 ±
4.9 mg/kg) (p < 0.05). The mean trough pre-dialysis concentrations were 10.7 ± 3.9 mg/l and 11.3 ± 5.6 mg/l at 48 and
72 h, respectively. These levels always largely exceeded the EUCAST susceptibility breakpoints for all the targeted bacteria
(>1 mg/l) with the exception of Pseudomonas aeruginosa (>8 mg/l). Cefepime concentrations were higher in anuric
patients compared to those with preserved diuresis (15.6 ± 3.5 vs 9.25 ± 3.6 mg/l; p < 0.001) and decreased on average by
81 % during dialysis (from 10.5 ± 3.7 to 1.96 ± 1.2 mg/l; p < 0.001). The clinical outcome of all patients was good.
Conclusions: Outpatient treatment with cefepime administered post-dialysis three-times-weekly was effective and
well-tolerated in our patients. According to our data, in patients infected by highly susceptible pathogens a fixed dose
of cefepime of 1 g before every 48-h interval and of 1.5 g before every 72-h interval should be recommended, without
need of routine monitoring of the cefepime blood levels. In patients having an infection with less susceptibles
pathogens as P. aeruginosa, and particularly in those among them exhibiting residual renal function, higher initial
doses are necessary (1.5 g before a 48-h interval and 2.0 g before a 72-h interval) with adaption according to the
subsequent pre-dialysis trough serum levels.
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Background
Chronic hemodialysis (HD) patients are at a high risk of
developing infectious complications due to their fragility
and state of relative immunodeficiency [1–3]. The need
for vascular access (i.e. autologous fistula, prosthetic graft
or central venous catheter) also increases this risk and
infection remains the second leading cause of death after
cardiovascular disease in HD patients [1–5]. Managing
severe infections most often requires intravenous (IV)
antibiotics and thus these patients must be hospitalized
for IV treatment. The use of post-dialysis therapy is inter-
esting, because it facilitates the option of managing even
severe infections with IV antibiotics on an outpatient
basis. This may shorten or avoid hospitalization and
improve the quality of life while in the interim reducing
treatment costs. Furthermore, prescribing an IV anti-
biotic after dialysis is associated with 100 % compliance
which is clearly better than the estimated compliance
of approximately 70 % associated with taking an oral
medication [6–8].
Because of its very prolonged half-life in HD patients,
post-dialysis vancomycin has been used in dialysis centers
for a long time [9]. However, vancomycin has a narrow
spectrum of action which is limited to Gram-positive
microorganisms. Therefore, some years ago, we also
started to use post-dialysis IV ceftriaxone with quite
satisfactory results [10]. Since reimbursement for ceftriax-
one in outpatient therapy is restricted in Switzerland, we
subsequently considered the possibility of using cefepime
instead. Cefepime is a fourth-generation cephalosporin
developed in the early 1990s with a broad spectrum of
action against both Gram-positive and Gram-negative
bacteria including Enterobacter sp., Citrobacter sp. and
Pseudomonas aeruginosa, but without an effect on strictly
anaerobic bacteria or resistant strains such as methicillin-
resistant Staphylococcus aureus (MRSA) and extended
spectrum beta-lactamase-producing (ESBL) Enterobacteria-
ceae [11, 12]. Like the other beta-lactams, it acts by linking
the penicillin-binding-protein and inhibiting synthesis
of the peptidoglycan which leads to defects in the bac-
terial wall and cell death. The pharmacodynamics of
beta-lactam antibiotics are based on time-dependent
bactericidal activity [13].
Cefepime is primarily eliminated by the kidney in un-
changed form (85 %) with a half-life of approximately 2 h
in subjects with normal renal function, but elimination is
much longer - up to 22 h - in anuric patients on dialysis
[14]. Cefepime hydrochloride has a molecular weight of
571, is only slightly bound to plasma proteins (16-19 %)
and is quite effectively cleared by dialysis [14, 15]. Con-
cerning its use in HD patients, recommendations in the
literature differ greatly, but in general the daily administra-
tion of a single reduced dose is recommended. Cronquist
et al. propose administering 250 mg of cefepime daily [14],
Bennett et al. recommend that the standard daily dose be
reduced by 50–75 % [16] and official Swiss recommenda-
tions advise a dose of 500 mg once daily [17].
Pharmacodynamic studies of cefepime in patients with
impaired renal function in the early 1990s already sug-
gested that this antibiotic could be prescribed every 48 h
in dialyzed patients [14]. However, there are only 2 reports
concerning the post-dialysis use of cefepime and these are
both from the same Austrian group [18, 19]. They propose
prescribing a fixed post-dialysis dose of 2 g three-times-
weekly, but it should be noted that this dosage was associ-
ated with relatively high mean residual cefepime serum
concentrations, e.g. 23 ± 7 mg/l [18], that may be associ-
ated to an increased risk of neurotoxicity [20–22].
In light of all these data, we decided in 2012 to use
post-dialysis IV cefepime when indicated and to adapt
the prescribed dose according to the pre-dialysis trough
serum levels, adopting a therapeutic drug monitoring
(TDM) approach. The objective of the present study is
to report a retrospective analysis of our experience as
well as the pharmacokinetics of cefepime after post-
dialysis administration three times each week.
Methods
From June 2012 to December 2013, twelve cases of in-
fection which occurred in 9 HD patients of our dialysis
unit were treated with post-dialysis cefepime. In all these
patients cefepime was considered as a first choice anti-
biotic based on the clinical and microbiological data and
was prescribed at the appropriate dose (based on the
TDM approach used) as part of our standard clinical
cares. The medical records of these nine patients were
studied retrospectively, and all subjects retrospectively
gave their informed consent authorizing us to use their
demographic and medical data. According to the rules
of our Hospital based on the Cantonal Law (Loi du 16
novembre 1999 sur la santé; http://bdlf.fr.ch/frontend/
versions/4139?locale=fr 4139?locale = fr) the present study,
being retrospective, did not require formal review by
the Ethics Committee of our Institution (Commission
d'éthique pour les projets de recherche biomédicale du
Canton de Fribourg).
These nine patients (4 males/5 females) were dialyzed
due to chronic kidney disease associated with diabetic
(n = 4) and vascular (n = 1) nephropathy, glomerulo-
nephritis (n = 1), amyloidosis (n = 1) and multifactorial
CKD (n = 2). Their mean age and weight were 68.9 ±
6.8 years and 62.0 ± 11.9 kg, respectively (mean BMI
23.0 ± 3.5). Four of these patients were anuric and the
rest had a residual diuresis >400 ml/day (mean diuresis:
950 ± 250 ml/24 h; mean residual creatinine clearance:
3.2 ± 2.4 ml/min). All were dialyzed three times each
week with high-flux HD using one of the following high-
flux dialyzers: Polyflux 170H (Gambro), FX80 (Fresenius)
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or Sureflux 190UX (Nipro). Dialysis sessions were on aver-
age 4 h long, with blood flow rates averaging 300 ml/min
and a dialysate flow of 500 ml/min.
The sites of the treated infections were: lungs (n = 4),
urinary tract (n = 3), catheter-related (n = 2), skin, bone and
digestive tract (one each). The causal pathogens were iden-
tified in 7 cases in sputum (n = 2), wound smear (n = 1),
abscess (n = 1), urine (n = 2) and blood (n = 1).
The initial post-dialysis dose of cefepime (Cefepime
OrPha®, Orpha Swiss GMBH, Switzerland) was approxi-
mately 15 mg/kg and ranged from 750 to 1500 mg
(given as a 5–10 min infusion at the end of dialysis).
The higher doses of 1500 mg were mainly prescribed
before the 72-h interval of a weekend. The subsequent
doses were adapted when appropriate according to the
trough serum levels obtained before the following HD
session in order to remain above the European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST)
breakpoints for susceptible organisms [23, 24] and above
the MIC90 of a clinical collection of bacteria [11].
The residual plasma concentrations of cefepime
were determined before (n = 30) and after (n = 17) HD.
The cefepime concentrations were measured by liquid
chromatography-mass spectrometry (LC-MS/MS) in
the Clinical Pharmacology Laboratory, CHUV University
Hospital, Lausanne, Switzerland. The cefepime trough
levels generally recommended by this laboratory range
from 2 to 15 mg/l.
Statistical methods
The results are given as mean ± standard deviation. For
continuous variables, the difference between two groups
was assessed by the student’s t-test for unpaired data. All
tests were two-sided and significance was deemed to
exist for p < 0.05.
Results
Overall, the mean dose of post-dialysis cefepime was
920 ± 270 mg (14.5 ± 5.1 mg/kg), but it was significantly
lower before the 48-h interval (775 ± 210 mg or 12.7 ±
4.5 mg/kg) than before the 72-h interval (1125 ± 225 mg
or 17.2 ± 4.9 mg/kg) (p < 0.05). The mean pre-dialysis ce-
fepime concentrations were 10.7 ± 3.9 mg/l and 11.3 ±
5.6 mg/l at 48 and 72 h, respectively (p =NS). Fig. 1
shows the distribution of the pre-dialysis serum anti-
biotic concentrations and, with the exception of 3 values,
indicates that all the residual pre-dialysis concentrations
were higher than 6 mg/l. Table 1 shows that these levels
always largely exceeded the EUCAST susceptibility break-
points for all the targeted bacteria (>1 mg/l) with the excep-
tion of Pseudomonas aeruginosa for which the breakpoint
is much higher (>8 mg/l). The MIC90 for the reference
bacteria also was always reached except for P. aeruginosa.
We compared pre-dialysis cefepime serum levels of
patients with residual diuresis to those of the anuric
patients. While both groups received similar doses of
cefepime (p = NS), pre-dialysis concentrations were
significantly higher in the anuric patients when com-
pared to those with preserved diuresis (15.6 ± 3.5 vs
9.25 ± 3.6 mg/l, p < 0.001). In the anuric patients, all
the serum trough levels were >10 mg/l with only one
value >18 mg/l (see Fig. 1).
In 17 HD sessions, cefepime serum concentrations were
measured both before and after dialysis. Our data show that
cefepime is quite effectively removed during dialysis with a
mean 81.3 % reduction in serum levels from 10.5 ± 3.7 to
1.96 ± 1.2 mg/l (p < 0.001). In 77 % of the cases, post-HD
concentrations remained above >1 mg/l.
The clinical course of all our patients was favorable and
no significant side effects occurred. In two patients, anti-
biotic treatment was started during hospitalization and
then continued after discharge. In all the other patients,
treatment occurred entirely on an outpatient basis.
Discussion
Chronic hemodialysis (HD) patients are at a high risk of
developing infectious complications and infection is the
Fig. 1 Distribution of the pre-dialysis serum cefepime
concentrations (n = 30)
Table 1 EUCAST susceptibility breakpoints (ref. 20) and MIC90
values (ref. 11) of the identified organisms
Bacteria Breakpoint MIC90
(mg/l) (mg/l)
Enterobacter cloacae 1 4
Serratia odorifera 1 0.5
Pseudomonas aeruginosa (n = 2) 8 16
Staphylococcus aureus - 2
Klebsiella oxytoca 1 ≤0.25
Acinetobacter sp. - -
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second leading cause of death in this population after
cardiovascular disease [1–5]. As a result of this high
susceptibility to infection, dialysis patients often require
hospitalization for prolonged treatment with IV antibi-
otics. In this regard, post-dialysis intravenous administra-
tion of antibiotics is quite interesting since it facilitates the
management of even severe infections on an outpatient
basis with a 100 % compliance [6–8], and thus improves
the quality of life while reducing treatment costs. This
explains why vancomycin has been largely used after
dialysis for a long time in dialysis centers [9]. However,
vancomycin has a narrow spectrum of action which
limits its use to infections caused by Gram-positive mi-
croorganisms. Cefepime has a broader action spectrum
[11, 12] and a pharmacokinetic profile that may permit
intermittent post-dialysis administration three times
each week [14, 18, 19] and is therefore of great interest
from a clinical perspective.
Based on the pharmacokinetic studies with radiolabeled
cefepime conducted by Barbhaiya et al., it had already
been proposed in the early 1990s that cefepime could be
prescribed once every 48 h in patients with severely
impaired renal function [15]. In 1992, Cronqvist et al.
studied the pharmacokinetics of 1 g of cefepime admin-
istered in volunteers with various degrees of renal
impairment compared to healthy subjects and reported
that elimination of cefepime is mainly renal and corre-
lates closely and linearly to GFR with negligible tubular
secretion [14]. In five HD patients, the maximum serum
concentration after antibiotic infusion was slightly higher
(130 ± 23 mg/l) than in normal subjects. However, the
drug clearance was 15 times lower, the elimination half-
life was 12 times as long (up to 22 h) and the area under
the concentration-time curve (AUC) was 18 times higher
[14]. In 2000, Schmaldienst et al. reported on the pharma-
cokinetics of cefepime in 6 anuric HD patients who were
treated with high-flux dialyzers and received a fixed dose
of 2 g after each HD. In these patients, the mean peak
serum concentration was 166 ± 49 mg/l and the mean
trough levels were 23 ± 7 mg/l [18]. Based on their results,
these authors proposed the administration of a fixed dose
of 2 g three times each week in anuric HD patients. Five
years later, this same group reported on its clinical experi-
ences in treating 11 anuric HD patients according to that
protocol and reported a success rate of 82 % [19].
Although this Austrian group did not report significant
side effects in their patients, the relatively high cefepime
trough plasma concentrations which they measured were
initially of concern to us because severe neurological side
effects have been described with high levels of several
beta-lactam antibiotics including cefepime [20–22].
Recently, Lamoth et al. reported that the probability of
cefepime-associated neurological toxicity (i.e. altered
mental status, confusion, or myoclonia) increases steadily
with trough plasma levels exceeding 22 mg/l [21]. Another
concern regarding the regimen proposed by the Austrian
group is the fixed antibiotic dose which is administered
three-times-weekly. Our previous experience with post-
dialysis ceftriaxone administration [10] has shown us that
generally higher doses are required before a 3-day week-
end interval in order to achieve sufficient trough plasma
concentrations at the end of this period. Finally, these
authors limit their use of post-dialysis cefepime to anuric
patients which - of course - is not the condition of a large
number of HD patients, particularly among those starting
on a HD program [25].
Consistent with the concerns discussed above, we real-
ized that an approach based on the therapeutic drug moni-
toring (TDM) concept should facilitate the prescription of
a post-dialysis dose that is high enough to ensure adequate
trough plasma concentrations during the entire one-week
period while avoiding potentially toxic cefepime levels. As
shown in the results section, with the doses of cefepime we
prescribed the trough plasma concentrations were well
above the EUCAST breakpoints for susceptible organisms
in most individual patients and above the MIC90 of a rele-
vant clinical collection of bacteria with the exception of P.
aeruginosa. Using our approach, only one of our anuric
patients (on one occasion) had a trough level higher than
18 mg/l. It is worth noting that the cefepime doses which
we used in our patients were on average ≈ 50 % lower than
the fixed dose of 2 g after each dialysis proposed by the
aforementioned Austrian group [18, 19].
Mean cefepime concentrations were significantly lower
in our non-anuric patients. These lower concentrations
observed in patients still having residual diuresis suggest
that a certain amount of cefepime is still excreted in
urine and correlates with the fact that most of its elimin-
ation is related to the glomerular filtration rate [14]. There-
fore, in patients with residual diuresis the prescription of
higher doses of cefepime should be considered in order to
achieve plasma trough levels that are high enough. This
point is clearly crucial in patients who are suffering
from an infection caused by less susceptible bacteria
such as P. aeruginosa.
Finally, it should be noted that several previous studies
have already reported that cefepime is effectively cleared
during dialysis with a reduction rate ranging from 40 to
68 % during 3-h sessions [14, 18, 22]. Our data shows
that a 4-h session with high-flux dialyzers reduces the
drug by about 80 %. This point may be of interest to
patients who are suffering from side effects related to
cefepime accumulation (which occurs most often in
patients with renal dysfunction) and who can rapidly
improve after a single dialysis session [21, 22].
This study has some limitations. First, it is a retrospect-
ive cohort study conducted at a single center. Second, it
concerns a small number of patients. However it should
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be noted that all the patients were accurately monitored
and that, on average, 4 to 5 determinations of the cefe-
pime serum levels were performed in each patient. Also, a
strength of the present study is that it is the first one that
reports the data concerning the clinical use of post-
dialysis cefepime based a therapeutic drug monitoring
(TDM) approach. It should be noted, however, that a
potential limitation of this approach is the fact that
cefepime serum level measurement is not widely avail-
able at present time.
Conclusions
In conclusion, outpatient treatment with cefepime
administered after dialysis three-times-weekly proved to
be effective and well-tolerated in our patients while
reducing hospitalization and improving their quality of
life. According to the presented data, in patients having
infections with highly susceptible pathogens a fixed dose
of cefepime of 1 g before every 48-h interval and of 1.5 g
before every 72-h interval can be recommended, without
need of routine monitoring of the cefepime blood levels.
However in patients with suspected or proven infection
with less susceptible pathogens as P. aeruginosa and
particularly in those patients exhibiting significant residual
renal function higher initial doses should be prescribed,
i.e. 1.5 g before a 48-h interval and 2 g before a 72-h inter-
val. In this latter group of patients the quantification of
the drug’s levels is mandatory in order to adapt the subse-
quent doses to the patient’s trough serum levels.
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